- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Next HIX Challenge: Formulary, Network Comparison Tools
Left as-is, current exchange formuarly and network search technology has the potential for a lot of consumer dissatisfaction and backlash.
Left as-is, current exchange formuarly and network search technology has the potential for a lot of consumer dissatisfaction and backlash.
In just under half of the public exchanges, it is “difficult or impossible” for shoppers to figure out which drugs are covered by health plans, researchers at Avalere Health found in a study of 12 state-based and five federally-run exchanges.
In eight exchanges, plan formularies are either difficult to access, such as in Florida and New York, or almost impossible to find, with no online links to the drug lists in California, Massachusetts, Oregon, Rhode Island, Washington and Washington D.C.
In nine of the exchanges studied, formularies are at least moderately accessible, Avalere researchers found in the study, funded by Pfizer.
Read the full story here: http://bit.ly/1rObaF0
Source: Healthcare Payer News
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
AXS25: Health Policy, Drug Costs, and AI Highlights From the Conference
May 6th 2025Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.
Read More
